By Lina carolina 
Groundbreaking research from King’s College London has illuminated the intricate mechanisms by which a novel antibody treatment reactivates a patient’s own immune cells, offering a potent new strategy against ovarian cancer. This pioneering work, led by Professor Sophia Karagiannis, promises to deepen our understanding of patient responses to this innovative immunotherapy and pave the way for more effective cancer treatments. The findings, published today in the prestigious journal Nature Communications, were supported by a coalition of leading research bodies including Cancer Research UK, the Medical Research Council, and Breast Cancer Now.
A Paradigm Shift in Cancer Immunotherapy
Immunotherapy has emerged as a transformative approach in cancer care, empowering the body’s natural defenses to identify and neutralize malignant cells. Currently, the vast majority of antibody-based immunotherapies employed in oncology are derived from Immunoglobulin G (IgG) antibodies. While successful against many cancers, IgGs have historically demonstrated limited efficacy against ovarian cancer, a notoriously resilient and often late-diagnosed disease. This has created a significant unmet need for more effective therapeutic options.
The research team at King’s College London has achieved a world-first by developing a treatment utilizing a distinct class of antibodies: Immunoglobulin E (IgE). Unlike IgGs, which primarily engage immune cells circulating in the bloodstream, IgE antibodies possess a remarkable ability to bind with high affinity to immune cells residing within tissues. This characteristic is crucial for their known roles in orchestrating immune responses during allergic reactions and in combating parasitic infections. The King’s College London team has ingeniously leveraged these potent immune-stimulating properties of IgE to target solid tumors.
MOv18 IgE: A Unique Mechanism of Action
Central to this advancement is an IgE antibody known as MOv18. The researchers meticulously investigated its capacity to activate immune cells derived from ovarian cancer patients and its influence on the complex tumor microenvironment. Their findings reveal that MOv18 IgE operates through a unique, multi-pronged approach. It effectively reverses the immune suppression that is a hallmark of the ovarian cancer tumor microenvironment, thereby unleashing a cascade of diverse immune cell activations specifically directed against the cancer.
This novel mechanism was first glimpsed in a Phase Ia clinical trial, meticulously designed and executed by the King’s College London researchers. Conducted at the National Institute for Health and Care Research (NIHR) Guy’s and St Thomas’ Clinical Research Facility, in collaboration with Cancer Research UK’s Centre for Drug Development, the trial provided early indicators of MOv18 IgE’s promise. Notably, at low doses, MOv18 IgE achieved significant tumor shrinkage in a patient with ovarian cancer who had previously shown no response to conventional therapies. This clinical success underscored the urgent need to unravel the precise molecular and cellular pathways underlying MOv18 IgE’s efficacy.
Unraveling the Biology: Macrophages and T Cells in the Spotlight
The new study delves deeply into the biological underpinnings of MOv18 IgE’s action within the human ovarian cancer immune landscape. This multidisciplinary investigation, involving collaborations with esteemed institutions such as Guy’s and St Thomas’ NHS Foundation Trust, the Medical University of Vienna, Fondazione IRCCS Instituto Nazionale dei Tumori in Milan, and SeromYx Systems, Inc., focused on the intricate interactions between MOv18 IgE and key immune cell populations.
A primary focus was placed on macrophages, a type of immune cell typically responsible for engulfing and destroying pathogens and cellular debris. However, in the context of cancer, these vital cells can be subverted by the tumor. Ovarian cancer, for instance, can corrupt macrophages, diminishing their anti-cancer functions and reprogramming them to actively support tumor growth and survival. This corruption creates an immunosuppressive environment that shields the cancer from immune attack.
From Suppression to Activation: The Macrophage’s Transformation
Drawing upon previous research in animal models, which suggested that MOv18 IgE could reprogram corrupted macrophages towards an anti-cancer state, the King’s College London team sought to validate these findings in human ovarian cancer. They employed a sophisticated experimental design. First, they collected macrophages from healthy donors and exposed them to cancerous fluid samples aspirated from the peritoneal cavity—the primary site for ovarian cancer metastasis—of patients diagnosed with the disease. Concurrently, they isolated macrophages directly from these patient-derived cancerous fluid samples, providing a direct window into the tumor’s immune milieu. All patient samples were ethically sourced from Guy’s and St Thomas’ NHS Foundation Trust.
The results were compelling. In both experimental setups, the researchers observed that ovarian cancer significantly suppressed the immune activity of macrophages. Crucially, however, they demonstrated that MOv18 IgE could effectively bind to these suppressed macrophages and activate them, thereby restoring their ability to kill ovarian cancer cells.
Beyond this direct cytotoxic effect, the study revealed another critical mechanism. Through the activation of these macrophages, MOv18 IgE initiated a reversal of the suppressive influence that these cancer-associated macrophages exerted on other vital immune cells, namely T cells. T cells are widely recognized as the linchpins of adaptive immunity, playing a crucial role in orchestrating long-term, targeted immune responses against cancer. By neutralizing the immunosuppressive effects of macrophages, MOv18 IgE essentially clears the path for T cells to engage effectively with the tumor.
Expert Insights and Clinical Implications
Dr. Gabriel Osborn, who led this research as a PhD student at King’s College London, elaborated on the significance of these findings: "We discovered that in patients, ovarian cancer fundamentally re-programs macrophages, steering them away from their normal immune-activating roles. Instead, these corrupted macrophages form a tightly interwoven, immunosuppressive network in conjunction with T cells, effectively stifling anti-cancer immunity. MOv18 IgE, however, acts as a critical disruptor. It compels patient-derived macrophages to not only kill cancer cells but also to undergo a potent inflammatory activation. This inflammatory shift, in turn, reverses their previously suppressive effects on T cells. This study provides vital, patient-specific biological data that corroborates our earlier laboratory observations for MOv18 IgE and, for the first time, unequivocally demonstrates that IgE-mediated macrophage stimulation can invigorate the broader tumor immune system."
To further validate these in-vitro findings, the team examined tumor biopsies from two patients who had participated in the Phase Ia clinical trial. They analyzed samples collected before and after treatment with MOv18 IgE. The post-treatment biopsies revealed a marked increase in the numbers of both macrophages and T cells within the tumor tissue. This observation strongly suggests that these two immune cell populations are indeed key players in the anti-tumor activity mediated by MOv18 IgE.
Professor Sophia Karagiannis, Professor of Translational Cancer Immunology and Immunotherapy at King’s College London and the senior author of the study, emphasized the importance of fundamental research in advancing clinical applications: "A deep understanding of the underlying biology of a treatment is absolutely paramount to accelerating its journey from the laboratory to the patient’s bedside. We have identified that immune cells, which are typically inhibited within the tumor’s ‘microenvironment,’ are effectively redirected by IgE to specifically target and eliminate cancer cells. While our clinical investigations in patients are ongoing, it is imperative that we persist in our pursuit of comprehending how MOv18 IgE, and indeed a broader spectrum of IgE-based antibodies we are actively studying, can harness the immune system across diverse patient populations and cancer types."
Dr. Debra Josephs, a consultant medical oncologist at Guy’s and St Thomas’ NHS Foundation Trust and co-author of the study, who was instrumental in guiding the pre-clinical development of MOv18 IgE towards clinical trials, highlighted the translational aspect of the research: "Our overarching objective is to deepen our comprehension of the immune system and its complex interplay with cancer, with the ultimate aim of discovering more effective treatments for patients. During the pre-clinical development of MOv18 IgE, we established the critical role of activating and migrating tumor-associated macrophages into cancer lesions for this antibody treatment to achieve its therapeutic effect. This current research represents a significant stride forward in the development of MOv18 IgE, by enhancing our understanding of macrophage-mediated mechanisms, thereby bolstering the therapeutic potential of this novel antibody."
Professor James Spicer, Professor of Experimental Cancer Medicine at King’s College London, consultant in medical oncology at Guy’s and St Thomas’ NHS Foundation Trust, and the Chief Clinical Investigator of the MOv18 IgE Phase Ia trial, also a co-author, underscored the clinical imperative: "The pursuit of improved outcomes for our patients remains our primary focus. We are witnessing tangible progress through dedicated research into the immune system and the intricate environment in which cancer proliferates. In our ongoing research endeavors, we are striving to harness the inherent power of IgE to develop novel and effective treatments that can complement the established IgG antibody drugs currently in clinical use."
Broader Implications and Future Directions
The implications of this research extend beyond ovarian cancer. The fundamental understanding of how IgE antibodies can reprogram immunosuppressive macrophages and activate T cells offers a promising avenue for developing novel immunotherapies for a range of solid tumors. The success of MOv18 IgE in a challenging cancer like ovarian cancer, which has historically been difficult to treat with immunotherapy, signals a potential paradigm shift in the field.
The study also highlights the power of multidisciplinary collaboration, bringing together expertise in immunology, oncology, clinical research, and advanced molecular techniques. The ongoing clinical trials will be crucial in further evaluating the safety and efficacy of MOv18 IgE in larger patient cohorts. Future research will likely focus on identifying biomarkers that can predict patient response to IgE-based therapies and exploring combinations of MOv18 IgE with other cancer treatments to maximize therapeutic benefit. The research team’s commitment to exploring a wider panel of IgE-based antibodies suggests a strategic long-term vision for developing a new class of cancer immunotherapies.
The authors also expressed gratitude for the support from the Cancer Research UK City of London Centre and the King’s Health Partners Centre for Translational Medicine, recognizing their vital contributions to advancing this groundbreaking research. This sustained investment in fundamental science is critical for translating complex biological insights into tangible clinical benefits for patients battling cancer.
